A platform to test breast cancer treatments using patient-derived organ models.
Multi-organ metastatic breast cancer cell-based assay platform that models organotropic metastases using patient organoids in human tissue-derived ECMs to accelerate anti-metastatic drug development
This study is working on a new way to understand how breast cancer spreads to other parts of the body, using tiny models made from real patient tissues, to help find better treatments that are tailored just for you.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Xylyx Bio, INC. NIH-funded |
| Lab location | 1 site (Brooklyn, United States) |
| Project ID | NIH-11109706 on NIH RePORTER |
What this research studies
This research focuses on developing a novel assay platform that mimics how breast cancer spreads to different organs like bone, liver, and lung. By using patient-derived organoids and human tissue-derived extracellular matrices, the platform aims to create a more accurate model for studying metastatic breast cancer. This approach seeks to improve the prediction of how well potential anti-cancer drugs will work in real patients, ultimately accelerating the development of effective treatments. Patients may benefit from this research as it could lead to more personalized and effective therapies for metastatic breast cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic breast cancer, particularly those whose cancer has spread to the bone, liver, or lung.
Not a fit: Patients with early-stage breast cancer or those whose cancer has not metastasized may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with metastatic breast cancer.
How similar studies have performed: Other research has shown promise in using organoid models for cancer treatment testing, indicating that this approach could be effective.
Where this research is happening
Brooklyn, United States
- Xylyx Bio, INC. — Brooklyn, United States (Active)
Researchers
- Principal investigator: O'neill, John David — Xylyx Bio, INC.
- Study coordinator: O'neill, John David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.